GGrantIndex
← Leaderboards

Richard H Haubrich

University Of California San Diego

$4,482,274
Attributed
$5,299,673
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $683.1K · FY200519
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$5,299,673 · 7

By mechanism

K24$1,780,282 · 1
R01$1,634,799 · 1
P30$1,393,140 · 1
R21$424,875 · 1
M01$66,577 · 3

Top collaborators

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Pathogenesis

Research focus

PathogenesisClinical ResearchCohortClinicFundingMentorsFacultyLaboratoriesBaseSiteResistanceResearch PersonnelFailure (Biologic Function)ResourcesAdultCollaborationsCommunitiesPublicationsClinical TrialsAntiretroviral TherapyBehavioralAnti-Retroviral AgentsEvaluationFostering

Grant awards (30)

Screening for atherosclerotic vascular disease in HIV-infected children$311,364
R01 · FY2019 · HD
Screening for atherosclerotic vascular disease in HIV-infected children$319,363
R01 · FY2018 · HD
Screening for atherosclerotic vascular disease in HIV-infected children$327,548
R01 · FY2017 · HD
Screening for atherosclerotic vascular disease in HIV-infected children$331,979
R01 · FY2016 · HD
Screening for atherosclerotic vascular disease in HIV-infected children$344,545
R01 · FY2015 · HD
Improving Antiretroviral Management for HIV$193,058
K24 · FY2015 · AI · contact PI
Improving Antiretroviral Management for HIV$193,058
K24 · FY2014 · AI · contact PI
Improving Antiretroviral Management for HIV$193,058
K24 · FY2013 · AI · contact PI
Improving Antiretroviral Management for HIV$193,058
K24 · FY2012 · AI · contact PI
Clinical Investigation$114,643
P30 · FY2012 · AI · contact PI
Clinical Investigation$258,728
P30 · FY2011 · AI · contact PI
Improving Antiretroviral Management for HIV$193,058
K24 · FY2011 · AI · contact PI
Clinical Investigation$280,519
P30 · FY2010 · AI · contact PI
Improving Antiretroviral Management for HIV$170,129
K24 · FY2010 · AI · contact PI
Clinical Investigation$281,987
P30 · FY2009 · AI · contact PI
Assessing the Clinical Consequences of HIV Drug Resistance$231,750
R21 · FY2009 · AI · contact PI
Improving Antiretroviral Management for HIV$169,393
K24 · FY2009 · AI · contact PI
Clinical Investigation$224,224
P30 · FY2008 · AI · contact PI
Assessing the Clinical Consequences of HIV Drug Resistance$193,125
R21 · FY2008 · AI · contact PI
Improving Antiretroviral Management for HIV$161,022
K24 · FY2008 · AI · contact PI
Clinical Investigation$233,039
P30 · FY2007 · AI · contact PI
Improving Antiretroviral Management for HIV$159,669
K24 · FY2007 · AI · contact PI
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV -1 INFECTION$3,347
M01 · FY2007 · RR · contact PI
Improving Antiretroviral Management for HIV$154,779
K24 · FY2006 · AI · contact PI
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION$11,729
M01 · FY2006 · RR · contact PI
ACTG A5079 PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION IN HIV$3,910
M01 · FY2006 · RR · contact PI
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION$13,298
M01 · FY2005 · RR
ACTG A5079 PHYSIOLOGIC TESTOSTERONE SUPPLEMENTATION IN HIV$11,733
M01 · FY2005 · RR
ACTG A5079 Physiologic Testosterone Supplements in HIV$18,174
M01 · FY2004 · RR
ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION$4,386
M01 · FY2004 · RR